11 completed, 3 recruiting, 3 terminated, 2 active not recruiting. 9 Phase 2, 8 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 5, Recruiting 2, Active not recruiting 1, Terminated 1 |
| Phase 1 | 8 | Completed 7, Active not recruiting 1 |
| Phase 3 | 5 | Recruiting 2, Terminated 2, Active not recruiting 1 |
Follow Crinetics Pharmaceuticals Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-Drug Interaction Study of Atumelnant in Healthy Participants Atumelnant, Carbamazepine, Midazolam - Healthy Volunteers | Phase 1 | Completed | Crinetics Pharmaceuticals Inc. | 46 | 2026-05-28 | 2026-08-19 |
| A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH) Atumelnant, Placebo - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 2 / Phase 3 | Recruiting | Crinetics Pharmaceuticals Inc. | 153 | 2026-01-22 | 2026-10-16 |
| A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia Atumelnant, Placebo - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 3 | Recruiting | Crinetics Pharmaceuticals Inc. | 150 | 2025-12-11 | 2026-10-16 |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors CRN09682 - SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors | Phase 1 / Phase 2 | Active not recruiting | Crinetics Pharmaceuticals Inc. | 150 | 2025-11-26 | 2026-10-13 |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Paltusotine, Placebo - Carcinoid Syndrome, Carcinoid | Phase 3 | Active not recruiting | Crinetics Pharmaceuticals Inc. | 141 | 2025-11-19 | 2026-10-15 |
| A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants Atumelnant, Placebo - Healthy Volunteers | Phase 1 | Completed | Crinetics Pharmaceuticals Inc. | 21 | 2025-10-28 | 2026-03-11 |
| An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia atumelnant (CRN04894) - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 2 | Recruiting | Crinetics Pharmaceuticals Inc. | 200 | 2025-02-25 | 2026-06-29 |
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome atumelnant - Cushing Syndrome, Cushing Disease | Phase 1 / Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 19 | 2023-10-12 | 2026-10-14 |
| Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn) atumelnant (CRN04894) - Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 38 | 2023-07-03 | 2026-09-10 |
| Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Randomized: 40 mg Paltusotine, Randomized: 80 mg Paltusotine - Carcinoid Syndrome, Carcinoid | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 36 | 2022-04-22 | 2026-03-19 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) Paltusotine, Placebo - Acromegaly | Phase 3 | Terminated | Crinetics Pharmaceuticals Inc. | 111 | 2021-12-17 | 2026-07-15 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly Paltusotine, Placebo - Acromegaly | Phase 3 | Terminated | Crinetics Pharmaceuticals Inc. | 58 | 2021-05-12 | 2026-07-15 |
| Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers CRN04894 Oral Solution, Placebo Oral Solution - Healthy Volunteers | Phase 1 | Completed | Crinetics Pharmaceuticals Inc. | 88 | 2020-12-18 | 2023-09-21 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) Paltusotine - Acromegaly | Phase 2 | Terminated | Crinetics Pharmaceuticals Inc. | 43 | 2020-01-29 | 2026-07-29 |
| Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers [14C]-CRN00808, CRN00808 - Healthy Volunteers | Phase 1 | Completed | Crinetics Pharmaceuticals Inc. | 11 | 2019-09-17 | 2020-01-29 |
| A Single and Multiple-Ascending Dose Study of CRN01941 in Healthy Adult Volunteers CRN01941 Oral Solution, CRN01941 Oral Capsule, Placebo Oral Solution - Healthy Volunteers | Phase 1 | Completed | Crinetics Pharmaceuticals Inc. | 57 | 2019-04-29 | 2020-11-04 |
| An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) Paltusotine - Acromegaly | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 47 | 2019-03-12 | 2025-02-17 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) Paltusotine, Placebo - Acromegaly | Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 13 | 2019-03-11 | 2025-03-17 |
| Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers CRN00808, Placebo Oral Solution, Midazolam oral solution - Healthy Volunteers | Phase 1 | Completed | Crinetics Pharmaceuticals Inc. | 99 | 2017-09-22 | 2018-08-29 |
Acromegaly (5) · Adrenal Hyperplasia, Congenital (4) · Neuroendocrine Tumors (3) · Carcinoid Tumor (2) · Carcinoid Tumors, Intestinal (2) · Serotonin Syndrome (2) · ACTH Syndrome, Ectopic (1) · Carcinoma, Neuroendocrine (1) · Cushing Syndrome (1) · Neoplasm Metastasis (1) · Pituitary ACTH Hypersecretion (1)
Midazolam (2) · Carbamazepine (1) · Digoxin (1) · Metformin (1) · Random Allocation (1)
United States (16) · Brazil (11) · United Kingdom (9) · Argentina (8) · Germany (8) · Italy (8) · Poland (8) · France (5) · Hungary (5) · Australia (4) · Greece (4) · Serbia (4) · Belgium (3) · Netherlands (3) · Spain (3)
2018 (2), 2019 (1), 2023 (1)